1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
TDSPharm Co., Ltd.

TDSPharm Co., Ltd.

KKRX:464280
4,905.00
KRW
-185.00
(-3.63%)
974.21EPS
6.50P/E
33.48BMarket Cap
Nov 13Next Earn
TDSPharm Co., Ltd.
KRX:464280
(Korea Stock Exchange)

Recent

price

4,905.00

P/E

ratio

6.50

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
KRW
180,229.91
214,494.49
6,005.33
7,057.3
5,943.71
5,221.08
6,218.98
Revenue per Share
13,512.99
22,325.01
811
1,101
803
808
974.21
Basic EPS, GAAP
18,312.29
37,650.19
542.5
709.81
693.68
-1,720.89
-1,139.86
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
3,089.52
3,052.44
3,461.94
4,338.57
7,280.75
8,090.15
8,488.26
Book Value per Share
3,060.72
3,023.77
3,432.22
4,301.09
7,226.24
8,049.68
8,454.31
Tangible Book Value per Share
- -
- -
4
4
5
5
5
Basic Weighted Avg Shares
18,023
19,820
25,588
30,049
27,519
27,621
32,905
Sales/Revenue/Turnover
9
11.68
14.77
16.69
13.55
13.63
17.14
Operating Margin (%)
1,208
1,230
1,266
1,022
669
700
723
Depreciation Expense
1,351
2,063
3,456
4,688
3,718
4,275
5,155
Net Income, GAAP
17.28
14.71
10.15
14.6
11.73
14.04
16.27
Effective Tax Rate (%)
7.5
10.41
13.5
15.6
13.51
15.48
15.67
Profit Margin (%)
3,106
3,549
8,120
14,414
29,123
18,609
18,623
Working Capital
24
90
849
870
72
62
37
LT Debt
16,339
16,143
18,308
22,945
38,504
42,785
44,890
Total Equity
- -
8.29
13.65
15.12
8.51
6.64
8.9
Return on Invested Capital (%)
- -
9.31
15.05
17.87
10.47
9.31
10.24
Return on Capital (%)
- -
12.7
20.06
22.73
12.1
10.52
12.18
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
7,649
13,852
13,855
LT Borrowings
- -
- -
- -
LT Finance Leases
62
50
37
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
5
Market Capitalization
52,092
44,106
33,476

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
29,816
37,446
37,293
Cash, Cash Equivalents & STI
20,213
28,295
27,759
Accounts Receivable, Net
6,444
5,354
4,949
Inventories
2,597
3,236
3,977
Total Current Liabilities
11,206
17,919
18,670
Payables & Accruals
- -
- -
- -
ST Debt
7,649
13,852
13,855
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
23.29%
11.12%
Free Cash Flow
- -
-58.01%
-383.47%
Net Income, GAAP
- -
30.02%
14.97%
Sales/Revenue/Turnover
- -
9.69%
0.37%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,363
8,073
6,465
5,618
27,519
2025
5,277
5,583
8,082
8,678
27,621
2026
8,068
8,077
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
190
344
180
112.65
803
2025
69
162
276.09
300.48
808
2026
216.77
181
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Tdspharm Co., Ltd. Tdspharm Co., Ltd. (464280.KQ) develops, manufactures, and markets transdermal drug delivery systems (TDDS), pharmaceuticals, and cosmetics primarily in South Korea and internationally; its core products include general medicines, prescription drugs, non-medicinal products, cataplasma patches, plasta, fucidin band, antibiotics, pain medications, over-the-counter formulations, and advanced patch-based therapies leveraging proprietary adhesion, wet pack, and oral technologies. Founded in 2002 and headquartered at 253 Pangyo-ro, Bundang-gu, Seongnam-si, South Korea, the company targets healthcare providers, pharmacies, and consumers across Asia and select global markets with a focus on skin-absorbed drug delivery for pain relief, infections, and dermatological conditions. Tdspharm maintains ongoing research and development in TDDS pipelines, patent-protected innovations, and customized patch production services, with no major acquisitions, partnerships, funding rounds, or strategic shifts reported in the last 1-2 years as of late 2025.